Skip Ribbon Commands
Skip to main content

Find A Doctor

Associate Professor David Tan Shao Peng

Photo of Associate Professor David Tan Shao Peng
Credential:
BSc(Hons), MBBS(Hons)(London), PG Dip(Oncology), MRCP(UK)(Medical Oncology), PhD(London), FRCP(Edin)
Designation:
Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore
Visiting Consultant, Oncology – Medical & Radiation, Ng Teng Fong General Hospital
Associate Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore
Associate Chairman Medical Board (Research), National University Hospital (NUH)
Head, Innovation Transfer Office (Research Office), National University Health System (NUHS)
Specialty:
Cancer
Sub Specialty:
Haematology-Oncology, Medical Oncology
Medical and Surgical Conditions:
Baker cyst (Musculoskeletal Oncology), Brain Tumour, Breast Cancer, Bursitis (Musculoskeletal Oncology), Cervical Cancer, Chodromalacia (Musculoskeletal Oncology), Colorectal Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Gastric Cancer (Stomach Cancer), Gestational Trophoblastic Disease, Gynaecological Cancers, Hepatocellular Carcinoma, Infection (Musculoskeletal Oncology), Knee Arthritis (Musculoskeletal Oncology), Leukaemia, Liver Cancer, Lung Cancer, Lung Mass, Lymphoma, Mouth and Throat Cancers (Head & Neck), Mouth and Throat Cancers (Throat), Multiple Myeloma, Myeloproliferative Neoplasms (MPN), Nasopharyngeal Cancer, Nasopharynx Cancer, Oesophagus Cancer, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cancer, Prostate Cancer, Sarcoma, Skin Cancer, Vaginal Cancer, Vulvar Cancer, Womb Cancer (Uterine/Endometrial Cancer)
Special Interest:
Gynaecologic Cancer
Drug Development/ Phase I trials
Institution:
National University Hospital
National University Cancer Institute, Singapore
Ng Teng Fong General Hospital
National University Health System

Dr David Tan is a medical oncologist and clinician scientist at the National University Cancer Institute, Singapore. He is an Associate Professor at the Yong Loo Lin School of Medicine, NUS and also leads a laboratory at the Cancer Science Institute, NUS. His primary clinical and research interests are in gynaecological (ovarian, endometrial and cervical) cancers and the development of novel anti-cancer therapeutic agents.

Dr Tan graduated from Guy’s, King’s and St Thomas’ School of Medicine, University of London, UK with a BSc in Experimental Pathology (1st Class Honours) and MBBS with Distinction. He undertook training in internal medicine at Hammersmith Hospital and Guy’s and St Thomas’ Hospitals in London before being awarded a Cancer Research UK Research Fellowship at The Institute of Cancer Research in London, where he obtained his PhD in Oncology. He subsequently completed his specialist training in medical oncology at The Royal Marsden Hospital in London. After working in the Drug Development Unit at The Royal Marsden Hospital/ Institute of Cancer Research, he completed another fellowship at the Princess Margaret Cancer Centre, University of Toronto, Canada, in Drug Development and Gynaecologic Oncology before returning back to Singapore.

Dr Tan is currently the Associate Chairman Medical Board for Research at the National University Hospital, Singapore and Head of the Innovation Transfer Office at National University Health Systems (NUHS). He is also a member of the Novel Agents Committee for Cancer (NACC) at the Experimental Drug Development Centre in A*STAR Singapore. He is the founding President of the Gynecologic Cancer Group Singapore (GCGS), which is a national clinical trials network for gynaecologic cancers in Singapore, and sits on the Gynecologic Cancer InterGroup (GCIG) Executive Board of Directors. 


Education and Fellowships
BSc(Hons)(London), MBBS(Distinction)(London), PG Dip(Oncology), MRCP(UK)(Medical Oncology), PhD(London), FRCP(Edin)
2005-2008: Cancer Research UK Clinical Research Fellowship, The Institute of Cancer Research, London, UK - PhD
2008-2012: The Royal Marsden Hospital Medical Oncology Training Rotation, London, UK - Certificate of Completion of Training (CCT) in Medical Oncology and MRCP(UK)(Medical Oncology)
2012-2013: Fellowship in Gynaecologic Oncology and Drug Development, Princess Margaret Cancer Centre, University of Toronto, Canada 

Awards and Honours

1996 1st Year Distinction in Basic Medical Sciences, G
uy’s & St Thomas’ Hospitals Medical School, University of London
1998 BSc Prize for Experimental Pathology, Guy’s & St Thomas’ Hospitals Medical School, University of London
1999 3rd Year Merit Award, Guy’s King’s & St Thomas’ School of Medicine, University of London
2000 4th Year Merit Award, Guy’s King’s & St Thomas’ School of Medicine, University of London
2001 5th Year Merit Award, Guy’s King’s & St Thomas’ School of Medicine, University of London
2001 MBBS with Distinction, Guy’s King’s & St Thomas’ School of Medicine, University of London
2005 Cancer Research UK Clinical Research Fellowship Award
2007 Sir Alastair Currie Prize (Best Scientific Poster Presentation, 4th Meeting of the British Division of the IAP and the Pathological Society of Great Britain and Ireland)
2008 Young Investigator Award (5th European Congress: Perspectives in Gynaecologic Oncology, Cannes, France)
2011 Travelling Fellowship Award for the Helene Harris Memorial Trust 12th International Forum on Ovarian Cancer, Miami, Florida
2012 AACR-ECCO-ASCO Fellowship for FLIMS 14 Workshop on Methods in Clinical Cancer Research
2013 Singapore National Medical Research Council (NMRC) Transition Award
2014 European Society of Medical Oncology Travel Grant Award
2016 Singapore National Medical Research Council (NMRC) Clinician Scientist Award

Professional Memberships

American Society of Clinical Oncology
The Royal College of Physicians, London, UK
European Society of Medical Oncology


Research and Publications

  1. ​Matilda X. Lee, David SP Tan. Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?  J Gynecol Oncol. 2018 Nov;29(6):e96
  2. Tuan Zea Tan, Valerie Heong, Jieru Ye, Diana Lim, Jeffrey Low, Mahesh Choolani, Clare Scott, David Shao Peng Tan, and Ruby Yun-Ju Huang.  Decoding transcriptomic intra–tumour heterogeneity to guide personalised medicine in ovarian cancer.  The Journal of Pathology Oct 2018
  3. Natalie YL Ngoi, Darwin Tay, Valerie Heong, Yee Liang Thian, Pei Yi Ong, Samuel GW Ow, Anand D Jeyasekharan, Yi Wan Lim, Siew Eng Lim, Soo Chin Lee, Joseph Ng, Jeffrey JH Low, Arunachalam Ilancheran, Sharon ZL Koh, David SP Tan. A RAD response: Reversal of malignant bowel obstruction with platinum-based chemotherapy and olaparib in recurrent short platinum-free interval RAD51C germline mutation-associated ovarian cancer.  JCO (Journal of Clinical Oncology) Precision Oncology, July 2018
  4. Michal M Hoppe, Raghav Sundar, David S P Tan, Anand D Jeyasekharan, Biomarkers for Homologous Recombination Deficiency in Cancer. Journal of the National Cancer Institute, djy085, https://doi.org/10.1093/jnci/djy085. Published:18 May 2018
  5. Gloria H.J. Chan, Pei Yi Ong, Jeffrey J.H. Low, Hwai Loong Kong, Samuel G.W. Ow, David S.P. Tan, Yi Wan Lim, Siew Eng Lim and Soo-Chin Lee.  Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers. Oncotarget, 2018, Vol. 9, (No. 55), pp: 30649-30660
  6. Heong V, Syn NL, Lee XW. Sapari NS, Koh XQ, Adam Isa ZF, Sy Lim J, Lim D, Pang B, Thian YL, Ng LK, Wong AL, Soo RA, Yong WP, Chee CE, Lee SC, Goh BC, Soong R, Tan DSP. Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study. Int J Cancer. 2017 Oct 9. 
  7. Joline S. J. Lim and David S. P. Tan. Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers (Basel). 2017 Aug; 9(8): 109. Published online 2017 Aug 22. doi: 10.3390/cancers9080109. PMCID: PMC5575612.
  8. David SP Tan, Stan Kaye. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different? American Society of Clinical Oncology Education Book. 2015:114-21.
  9. Wong AL, Lim JS, Sinha A, Gopinathan A, Lim R, Tan CS, Soh T, Venkatesh S, Titin C, Sapari NS, Lee SC, Yong WP, Tan DS, Pang B, Wang TT, Zee YK, Soong R, Trnkova Z, Lathia C, Thiery JP, Wilhelm S, Jeffers M, Goh BC. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. J Transl Med. 2015 Feb 12;13:57.
  10. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Emma Kipps, David SP Tan, Stan B Kaye. Nature Reviews Cancer 2013 Apr;13(4):273-82.
  11. David SP Tan, Timothy A Yap, Margaret Hutka, Patricia Roxburgh, Jooern Ang, Susana Banerjee, Ewa Grzybowska, Charlie Gourley, Martin E Gore, Stan B Kaye. Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. European Journal of Cancer 2012 Dec 19.
  12. Alan Mackay, Britta Weigelt, Anita Grigoriadis, Bas Kreike, Rachael Natrajan, Roger A’Hern, David SP Tan, Mitch Dowsett, Alan Ashworth, Jorge S Reis-Filho. Microarray-based class discovery for molecular classification of breast cancer: analysis of inter-observer agreement. Journal of the National Cancer Institute 2011 Apr 20;103(8):662-73.
  13. David SP Tan, Marjan Iravani, W Glenn McCluggage, Maryou Lambros, Fernanda Milanezi, Alan Mackay, Charlie Gourley, Felipe C Geyer, Radost Vatcheva, Joanne Millar, Karen Thomas, Rachael Natrajan, Kay Savage, Kerry Fenwick, Alistair RW Williams, Charles Jameson, Mona El-Bahrawy, Martin Gore, Hani Gabra, Stanley B Kaye, Alan Ashworth and Jorge S Reis-Filho. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clinical Cancer Research 2011 Mar 15;17(6):1521-34.
  14. Richard Baird, David SP Tan, Stan B Kaye. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nature Reviews Clinical Oncology 2010 Oct;7(10):575-82.
  15. Britta Weigelt, Alan Mackay, Roger A’hern, Rachael Natrajan, David SP Tan, Mitch Dowsett, Alan Ashworth, and Jorge S Reis-Filho. Breast cancer molecular profiling: a retrospective analysis of molecular subtype assignment using single sample predictors. Lancet Oncology 2010 Apr;11(4):339-49.
  16. David SP Tan, Maryou BK Lambros, Sydonia Rayter, Rachael Natrajan, Radost Vatcheva, Qiong Gao, Caterina Marchiò, Felipe C Geyer, Kay Savage, Suzanne Parry, Kerry Fenwick, Narinder Tamber, Alan Mackay, Tim Dexter, Charles Jameson, W Glenn McCluggage, Alistair Williams, Ashley Graham, Dana Faratian, Mona El-Bahrawy, Adam J Paige, Hani Gabra, Martin E Gore, Marketa Zvelebil, Christopher J Lord, Stanley B Kaye, Alan Ashworth, Jorge S Reis-Filho. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clinical Cancer Research. 2009 Apr 1;15(7):2269-80.
  17. David SP Tan, Christian Rothermundt, Karen Thomas, Elizabeth Bancroft, Rosalind A Eeles, Susan Shanley, Audrey Ardern-Jones, Andrew Norman, Stanley B Kaye, Martin E Gore. The “BRCAness” Syndrome in Ovarian Cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 1/2 mutations. Journal of Clinical Oncology. 2008 Dec 1;26(34):5530-6.
  18. David SP Tan, Caterina Marchió, Robin L Jones, Kay Savage, Ian E Smith, Mitch Dowsett, Jorge S Reis-Filho. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Research and Treatment 2007 Oct 6
  19. David SP Tan, Roshan Agarwal, Stanley B Kaye. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncology 2006 Nov;7(11):925-34.